Literature DB >> 15153540

Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4.

Robin M Cisco1, Zeinab Abdel-Wahab, Jens Dannull, Smita Nair, Douglas S Tyler, Eli Gilboa, Johannes Vieweg, Yehia Daaka, Scott K Pruitt.   

Abstract

Maturation of dendritic cells (DC) is critical for the induction of Ag-specific immunity. Ag-loaded DC matured with LPS, which mediates its effects by binding to Toll-like receptor 4 (TLR4), induce Ag-specific CTL in vitro and in vivo in animal models. However, clinical use of LPS is limited due to potential toxicity. Therefore, we sought to mimic the maturation-inducing effects of LPS on DC by stimulating TLR4-mediated signaling in the absence of exogenous LPS. We developed a constitutively active TLR4 (caTLR4) and demonstrated that transfection of human DC with RNA encoding caTLR4 led to IL-12 and TNF-alpha secretion. Transfection with caTLR4 RNA also induced a mature DC phenotype. Functionally, transfection of DC with caTLR4 RNA enhanced allostimulation of CD4(+) T cells. DC transfected with RNA encoding the MART (Melan-A/MART-1) melanoma Ag were then used to stimulate T cells in vitro. Cotransfection of these DC with caTLR4 RNA enhanced the generation of MART-specific CTL. This CTL activity was superior to that seen when DC maturation was induced using either LPS or a standard mixture of cytokines (TNF-alpha, IL-6, IL-1beta, and PGE(2)). We conclude that transfection of DC with RNA encoding a functional signaling protein, such as caTLR4, may provide a new tool for studying TLR signaling in DC and may be a promising approach for the induction of DC maturation for tumor immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15153540     DOI: 10.4049/jimmunol.172.11.7162

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  EBV LMP1, a viral mimic of CD40, activates dendritic cells and functions as a molecular adjuvant when incorporated into an HIV vaccine.

Authors:  Sachin Gupta; James M Termini; Liguo Niu; Saravana K Kanagavelu; Helena Schmidtmayerova; Victoria Snarsky; Richard S Kornbluth; Geoffrey W Stone
Journal:  J Leukoc Biol       Date:  2011-05-17       Impact factor: 4.962

2.  mRNA-transfected Dendritic Cells Expressing Polypeptides That Link MHC-I Presentation to Constitutive TLR4 Activation Confer Tumor Immunity.

Authors:  Gal Cafri; Adi Sharbi-Yunger; Esther Tzehoval; Zoya Alteber; Tamar Gross; Ezra Vadai; Alon Margalit; Gideon Gross; Lea Eisenbach
Journal:  Mol Ther       Date:  2015-05-22       Impact factor: 11.454

Review 3.  mRNA-based therapeutics--developing a new class of drugs.

Authors:  Ugur Sahin; Katalin Karikó; Özlem Türeci
Journal:  Nat Rev Drug Discov       Date:  2014-09-19       Impact factor: 84.694

Review 4.  Mammalian Toll-like receptors: to immunity and beyond.

Authors:  P A Hopkins; S Sriskandan
Journal:  Clin Exp Immunol       Date:  2005-06       Impact factor: 4.330

5.  Dendritic cell immunotherapy in uterine cancer.

Authors:  An Coosemans; Sandra Tuyaerts; Anke Vanderstraeten; Ignace Vergote; Frédéric Amant; Stefaan W Van Gool
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs.

Authors:  Michael C Brown; Eda K Holl; David Boczkowski; Elena Dobrikova; Mubeen Mosaheb; Vidya Chandramohan; Darell D Bigner; Matthias Gromeier; Smita K Nair
Journal:  Sci Transl Med       Date:  2017-09-20       Impact factor: 17.956

7.  Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4.

Authors:  Guang-Nian Zhao; Peng Zhang; Jun Gong; Xiao-Jing Zhang; Pi-Xiao Wang; Miao Yin; Zhou Jiang; Li-Jun Shen; Yan-Xiao Ji; Jingjing Tong; Yutao Wang; Qiao-Fang Wei; Yong Wang; Xue-Yong Zhu; Xin Zhang; Jing Fang; Qingguo Xie; Zhi-Gang She; Zhihua Wang; Zan Huang; Hongliang Li
Journal:  Nat Med       Date:  2017-05-08       Impact factor: 53.440

Review 8.  Engineering dendritic cells to enhance cancer immunotherapy.

Authors:  Jeanette E Boudreau; Aude Bonehill; Kris Thielemans; Yonghong Wan
Journal:  Mol Ther       Date:  2011-04-05       Impact factor: 11.454

Review 9.  Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification.

Authors:  Karine Breckpot; David Escors
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2009-12       Impact factor: 2.895

10.  MODULATING CO-STIMULATION DURING ANTIGEN PRESENTATION TO ENHANCE CANCER IMMUNOTHERAPY.

Authors:  Therese Liechtenstein; Ines Dufait; Alessio Lanna; Karine Breckpot; David Escors
Journal:  Immunol Endocr Metab Agents Med Chem       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.